Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI …

D Chan, RN Doughty, J Mazengarb… - The New Zealand …, 2020 - search.proquest.com
AIMS: To describe the use of evidence-based heart failure therapies in patients with reduced
left ventricular ejection fraction (LVEF) following acute coronary syndrome (ACS) …

Evidence-based heart failure therapies at discharge of patients with acute coronary syndromes and reduced ejection fraction: Data from the ACSIS survey

B Zafrir, T Ovdat, M Abu Akel, F Bahouth… - European Heart …, 2023 - academic.oup.com
Background Guideline-directed medical therapies for heart failure (HF) may benefit patients
with reduced left ventricular ejection fraction (LVEF) following acute coronary syndromes …

Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey

B Zafrir, T Ovdat, M Abu Akel, F Bahouth… - Journal of Personalized …, 2023 - mdpi.com
Background: Guideline-directed medical therapies for heart failure (HF) may benefit patients
with reduced left ventricular ejection fraction (LVEF) following acute coronary syndromes …

Management and long-term outcome of acute coronary syndrome patients presenting with heart failure in a contemporary New Zealand cohort (ANZACS-QI 4)

SHA Kueh, G Devlin, M Lee, RN Doughty… - Heart, Lung and …, 2016 - Elsevier
Background Acute heart failure (HF) associated with an acute coronary syndrome (ACS)
predicts adverse outcome. There have been important recent improvements in ACS …

Target doses of secondary prevention medications are not being achieved in patients with reduced left ventricular ejection fraction after acute coronary syndrome …

D Chan, RN Doughty, M Lund, M Lee… - Heart, Lung and Circulation, 2020 - Elsevier
Background Patients with reduced left ventricular ejection fraction (EF< 40%) are at high risk
for adverse outcomes and benefit from evidence based doses of angiotensin converting …

[PDF][PDF] Лікування серцевої недостатності зі зниженою фракцією викиду після гострого коронарного синдрому: дані дослідження ACSIS

B Zafrir - Crit. Care, 2023 - ifp.kiev.ua
Background. Guideline-directed medical therapies for heart failure (HF) may benefit patients
with reduced left ventricular ejection fraction (LVEF) following acute coronary syndromes …

Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry

SJ Greene, JA Ezekowitz, KJ Anstrom… - Journal of cardiac …, 2022 - Elsevier
Background For patients hospitalized for heart failure with reduced ejection fraction (HFrEF),
guidelines recommend optimization of medical therapy prior to discharge. The degree to …

Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients with Reduced LV Systolic Function After Acute Coronary Syndrome in New …

D Chan, M Lee, A Kerr - Heart, Lung and Circulation, 2018 - heartlungcirc.org
Background: Patients with reduced ejection fraction (rEF, LVEF< 40%,) are at high risk for
adverse outcomes and benefit from evidence based doses of angiotensin converting …

Prognostic significance of mid-range ejection fraction following acute coronary syndrome (ANZACS-QI 23).

D Chan, RN Doughty, M Lund, M Lee, K Poppe… - 2021 - researchspace.auckland.ac.nz
Aim Recommendations regarding medication use after acute coronary syndrome (ACS) are
dichotomised according to whether left ventricular ejection fraction (LVEF) is< 40% or≥ …

Patient eligibility for established and novel guideline-directed medical therapies after acute heart failure hospitalization

N Moghaddam, NM Hawkins, R McKelvie, S Poon… - Heart Failure, 2023 - jacc.org
Background Acute heart failure (AHF) hospitalization presents an opportunity to optimize
pharmacotherapy to improve outcomes. Objectives This study's aim was to define eligibility …